Overview: Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines and vaccines across areas such as cardiovascular disease, migraine, cancer, rare diseases, and infectious disease, including COVID 19.<\/p>\n
Operations: Pfizer generates most of its US$63.0b in revenue from its Global Biopharmaceuticals Business at about US$61.9b, with a smaller contribution of roughly US$1.4b from its Pfizer Centreone contract manufacturing unit.<\/p>\n
Market Cap: US$146.4b<\/p>\n
Pfizer sits at the intersection of large scale drug development and rapid change in healthcare, with a broad portfolio in oncology, vaccines, rare diseases, and a growing obesity and GLP 1 pipeline that aims to offset looming patent expiries for key products like Ibrance and Xtandi. The company is leaning into AI supported R&D and decision making, while Q1 2026 results highlighted 22% operational growth from newer and acquired products, including Padcev and Eliquis. At the same time, earnings have come under pressure. Revenue is forecast to decline over the next few years, and the dividend, while high at about 6.7%, is not fully supported by earnings or free cash flow. That mix of pipeline potential and real risk is what makes Pfizer worth a closer look.<\/p>\n
Pfizer\u2019s high dividend and AI supported pipeline could be masking an underappreciated risk reward profile that hinges on a few key products, so review the 1 key reward and 4 important warning signs (3 are major!)<\/a><\/p>\n Overview: Tempus AI is a healthcare technology company that uses an AI enabled data platform to help doctors and drug developers interpret genomic, clinical, and imaging data for cancer and other conditions, combining in house diagnostic testing with software tools for treatment decisions, clinical trial matching, and research.<\/p>\n Operations: Tempus AI generates around US$1.4b in revenue from Medical Labs and Research services in the United States.<\/p>\n Market Cap: US$9.0b<\/p>\n Tempus AI sits at the center of AI driven precision medicine, linking its own testing labs to a large data platform that biopharma clients and hospitals already pay for, with Q1 2026 revenue of US$348.12m and particularly strong growth from data applications in its Insights segment. For investors, the appeal is a mix of rising testing volumes, deep partnerships with large drug companies, and an expanding toolkit of AI products across oncology and genetics. The catch is that Tempus AI is still reporting sizeable losses and relies on external funding, with recent insider selling adding another question mark. That tension between rapid expansion and unresolved profitability may encourage some investors to examine the stock more closely as a potential way to gain exposure to AI in healthcare.<\/p>\n Tempus AI\u2019s accelerating data flywheel and AI tools could be masking a very different risk reward skew, so review the analysis report for Tempus AI<\/a> to see what the current numbers might be hinting at next.<\/p>\n Overview: Medtronic is a global medical device company that sells pacemakers, surgical tools, spinal and brain implants, insulin pumps, and other hardware and software that doctors use to treat cardiovascular, neurological, surgical, and diabetes related conditions.<\/p>\n Operations: Medtronic generates most of its roughly US$35.5b in revenue from Cardiovascular at US$13.5b, Neuroscience at US$10.2b, Medical Surgical at US$8.6b, and Diabetes at US$3.0b, with additional smaller contributions from other items and adjustments.<\/p>\n Market Cap: US$97.8b<\/p>\n Medtronic brings together AI powered surgical platforms, robotics, and advanced cardiac and brain therapies. This helps explain why earnings are forecast to grow faster than revenue and why analysts see scope for the stock to trade above current levels. The company backs this with a 3.73% dividend yield, high earnings quality, and strong governance. Recent CE Marks and FDA Breakthrough designations for pulsed field ablation and brain stimulation products also show how its pipeline is being turned into commercial products across multiple therapy areas. At the same time, modest 9.4% ROE and reliance on higher risk external borrowing mean investors still need to weigh balance sheet structure and returns on capital carefully.<\/p>\n Accelerating AI powered devices, robotics, and a 3.73% dividend yield make Medtronic look like a steady compounder. However, the real story sits in its future growth mix, so review the analyst forecasts for Medtronic<\/a> and see what might be hiding behind that modest 9.4% ROE.<\/p>\n The three stocks here are just a starting point, with the full Transformative Artificial intelligence (AI) Healthcare Stocks screener<\/a> surfacing 31 more companies whose AI driven healthcare stories could be just as compelling. Identify and analyze the specific catalysts, data flywheels, and AI use cases that matter to you so Simply Wall St can help you focus on the highest conviction opportunities in this theme.<\/p>\n Take Control of Your Investment Journey <\/p>\n If Tempus AI or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist<\/a> to monitor the share price against the fair value and track any new developments as they happen. Seeking Fresh Alternatives Beyond Your Radar <\/p>\n Fresh stock ideas rarely stay under the radar for long, and price momentum can change once the crowd catches on. Scan these curated lists before the next potential breakout.<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data New: Manage All Your Stock Portfolios in One Place<\/p>\n We’ve created the ultimate portfolio companion for stock investors, and it’s free.<\/p>\n \u2022 Connect an unlimited number of Portfolios and see your total in one currency Try a Demo Portfolio for Free<\/a><\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"AI in healthcare sits at the crossroads of powerful themes investors are already watching, from inflation and tighter…\n","protected":false},"author":2,"featured_media":665628,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-665627","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/665627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=665627"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/665627\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/665628"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=665627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=665627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=665627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"NYSE:PFE](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/1778574618_940_earnings-and-revenue-growth.png\")
<\/a>NYSE:PFE Earnings & Revenue Growth as at May 2026 Tempus AI (TEM)<\/a> <\/p>\n![\"NasdaqGS:TEM](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/1778574620_135_earnings-and-revenue-growth.png\")
<\/a>NasdaqGS:TEM Earnings & Revenue Growth as at May 2026 Medtronic (MDT)<\/a> <\/p>\n![\"NYSE:MDT](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/1778574622_972_earnings-and-revenue-growth.png\")
<\/a>NYSE:MDT Earnings & Revenue Growth as at May 2026 <\/p>\n
\n Once you’ve made your move, manage your holdings with our Portfolio Command Center<\/a> that filters out the noise to deliver only the most critical, actionable updates.
\n Throughout your journey, our Community<\/a> allows you to filter the best ideas from thousands of investor perspectives.
\n By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.\n <\/p>\n
\n and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
\n financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
\n Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
\n Simply Wall St has no position in any stocks mentioned.<\/p>\n
\u2022 Be alerted to new Warning Signs or Risks via email or mobile
\u2022 Track the Fair Value of your stocks<\/p>\n